Change search
ReferencesLink to record
Permanent link

Direct link
Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Umeå University, Faculty of Medicine, Radiation Sciences, Oncology.
Umeå University, Faculty of Medicine, Medical Biosciences, Clinical chemistry.
Umeå University, Faculty of Medicine, Radiation Sciences, Oncology.
Umeå University, Faculty of Medicine, Radiation Sciences, Oncology.
Show others and affiliations
2007 (English)In: Acta Oncologica, ISSN 0284-186X, Vol. 46, no 7, 951-960 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2007. Vol. 46, no 7, 951-960 p.
URN: urn:nbn:se:umu:diva-16740DOI: doi:10.1080/02841860701253045OAI: diva2:156413
Available from: 2007-10-10 Created: 2007-10-10 Last updated: 2012-04-03Bibliographically approved
In thesis
1. Experimental studies in brain tumours: with special regard to multidrug resistance and the ErbB-family
Open this publication in new window or tab >>Experimental studies in brain tumours: with special regard to multidrug resistance and the ErbB-family
2005 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Primary brain tumours, and especially the most common form malignant gliomas, usually display a pronounced resistance to other treatment modalities when surgery fails to cure. Growth factors, such as EGF and its receptor, frequently amplified and overexpressed in malignant gliomas, and factors associated with multidrug resistance have been suggested to at least partially explain the poor outcome. The aim of this thesis was to characterise factors in primary brain tumours associated with the development of resistance with focus on the epidermal growth factor receptor (ErbB) family, and multidrug resistance (MDR).

Influences of irradiation on the expression and activity of P-glycoprotein (Pgp) in malignant gliomas was evaluated. The effects showed that irradiation increased the efflux activity of Pgp in rat brain vascular endothelial cells, but not in glioma cells. In the intracranial BT4C glioma model, Pgp was detected in the capillary endothelium in the tumour tissue but not in glioma cells.

Expression of several factors coupled to MDR (Pgp, MRP1, LRP, and MGMT) in primary brain tumours were analysed and correlated to clinical data. In gliomas, Pgp and MRP1 were predominantly observed in capillary endothelium and in scattered tumour cells, whereas LRP occurred only in tumour cells. In meningiomas, expression of the analysed markers was demonstrated in the capillary endothelium, with a higher expression of Pgp and MRP1 in transitional compared to meningothelial meningiomas. A pronounced expression of MGMT was found independently of the histopathological grade or tumour type. Survival analysis indicated a shorter overall survival for patients suffering from low-grade gliomas with high expression of Pgp.

To explore the importance of the epidermal growth factor receptor (EGFR), expression levels of the family members (EGFR, ErbB2-4) were analysed and their relations to various clinical parameters were evaluated in gliomas and meningiomas. In gliomas, the highest EGFR expression was observed in high-grade tumours, while ErbB4 expression was most pronounced in low-grade tumours. In meningiomas, expression of EGFR, ErbB2, and ErbB4 was observed in the majority of the tumours. An intriguing observation in low-grade gliomas was a significantly decreased overall survival for patients with high EGFR protein expression.

The effects of different time schedules for administration of the selective EGFR inhibitor ZD1839 in relation to irradiation of glioma cells were analysed. The analyses showed a heterogeneity in the cytotoxic effects of ZD1839 between cell lines, and it was obvious that some of the cell lines showed sensitivity to ZD1839 despite no or low expression of EGFR. The study also demonstrated the importance of timing of ZD1839 administration when this agent is combined with irradiation.

In conclusion, in order to enhance the efficacy of radiotherapy by various drugs in malignant gliomas it may be essential to inhibit drug efflux activity in endothelial cells and to deliver drugs in an optimal timing in relation to radiotherapy. The heterogeneity in expression of drug resistance markers, as well as the ErbB family reflects the complexity in classification of primary brain tumours, and indicates that subgroups of patients with low-grade gliomas expressing Pgp and EGFR might benefit from more aggressive and individualised treatment.

Place, publisher, year, edition, pages
Umeå: Strålningsvetenskaper, 2005. 80 p.
Umeå University medical dissertations, ISSN 0346-6612 ; 959
Oncology, glioma, meningioma, endothelium, MDR, Pgp, MRP1, LRP, MGMT, EGFR, ErbB2, ErbB3, ErbB4, Onkologi
National Category
Cancer and Oncology
Research subject
urn:nbn:se:umu:diva-521 (URN)91-7305-863-7 (ISBN)
Public defence
2005-05-20, Sal 244, Lionssalen, By 7, Norrlands Universitetssjukhus, UMEÅ, 12:00 (English)
Available from: 2005-04-28 Created: 2005-04-28 Last updated: 2012-04-03Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Andersson, UlrikaJohansson, DavidJohansson, MikaelMalmer, Beatrice
By organisation
OncologyClinical chemistry

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 39 hits
ReferencesLink to record
Permanent link

Direct link